Analyst Price Target is $23.00
▲ +693.10% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Audentes Therapeutics in the last 3 months. The average price target is $23.00, with a high forecast of $25.00 and a low forecast of $20.00. The average price target represents a 693.10% upside from the last price of $2.90.
Current Consensus is
Moderate Buy
The current consensus among 3 investment analysts is to moderate buy stock in Audentes Therapeutics. This rating changed within the last month from a Buy consensus rating.
Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It is also developing vectorized antisense treatments for the treatment of duchenne muscular dystrophy and myotonic dystrophy type 1. The company has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and a license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. Audentes Therapeutics, Inc. was founded in 2012 and is headquartered in San Francisco, California.
Read More
